Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion

Exp Neurol. 2011 Oct;231(2):261-71. doi: 10.1016/j.expneurol.2011.06.019. Epub 2011 Jul 14.


One treatment approach for lysosomal storage diseases (LSDs) is the systemic infusion of recombinant enzyme. Although this enzyme replacement is therapeutic for the viscera, many LSDs have central nervous system (CNS) components that are not adequately treated by systemic enzyme infusion. Direct intracerebroventricular (ICV) infusion of a high concentration of recombinant human acid sphingomyelinase (rhASM) into the CNS over a prolonged time frame (hours) has shown therapeutic efficacy in a mouse model of Niemann-Pick A (NP/A) disease. To evaluate whether such an approach would translate to a larger brain, rhASM was infused into the lateral ventricles of both rats and Rhesus macaques, and the resulting distribution of enzyme characterized qualitatively and quantitatively. In both species, ICV infusion of rhASM resulted in parenchymal distribution of enzyme at levels that were therapeutic in the NP/A mouse model. Enzyme distribution was global in nature and exhibited a relatively steep gradient from the cerebrospinal fluid compartment to the inner parenchyma. Additional optimization of an ICV delivery approach may provide a therapeutic option for LSDs with neurologic involvement.

MeSH terms

  • Animals
  • Brain / enzymology
  • Brain / metabolism*
  • Female
  • Infusions, Intraventricular
  • Macaca mulatta
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacokinetics*
  • Sphingomyelin Phosphodiesterase / administration & dosage
  • Sphingomyelin Phosphodiesterase / pharmacokinetics*


  • Recombinant Proteins
  • acid sphingomyelinase-1
  • Sphingomyelin Phosphodiesterase